Skip to main content
  • En
  • Français

Top Navigation

  • Newsroom
  • Contact Us

Main navigation

  • About Us
  • Products
  • Technology
  • Clinical Studies
  • Investors
  • News
  • En
  • Français

2013

Bone Therapeutics Raises €7.7 Million in Series D Fundraising

  • Read more about Bone Therapeutics Raises €7.7 Million in Series D Fundraising

Bone Therapeutics Invests in Cell Therapy Manufacturing Facility

  • Read more about Bone Therapeutics Invests in Cell Therapy Manufacturing Facility

Bone Therapeutics Awarded Manufacturing Authorisation and European Approval to Produce Allogeneic Bone Cell Therapy Products

  • Read more about Bone Therapeutics Awarded Manufacturing Authorisation and European Approval to Produce Allogeneic Bone Cell Therapy Products

Bone Therapeutics to Present at Upcoming Investor Conferences

  • Read more about Bone Therapeutics to Present at Upcoming Investor Conferences

Bone Therapeutics and Erasme University Start Phase IIa Trial in Osteoporosis with its Cell Therapy Product PREOB®

  • Read more about Bone Therapeutics and Erasme University Start Phase IIa Trial in Osteoporosis with its Cell Therapy Product PREOB®

Fondation de la Plateforme Wallonne de Thérapie Cellulaire: La plateforme vise à produire les médicaments de thérapie cellulaire à grande échelle

  • Read more about Fondation de la Plateforme Wallonne de Thérapie Cellulaire: La plateforme vise à produire les médicaments de thérapie cellulaire à grande échelle

Bone Therapeutics Appoints Wim Goemaere as Chief Financial Officer

  • Read more about Bone Therapeutics Appoints Wim Goemaere as Chief Financial Officer

Bone Therapeutics receives clearance for ALLOB® phase I/IIa trial

  • Read more about Bone Therapeutics receives clearance for ALLOB® phase I/IIa trial

Bone Therapeutics treats first patients in PREOB® pivotal phase IIb/III trial for the treatment of non-union fractures

  • Read more about Bone Therapeutics treats first patients in PREOB® pivotal phase IIb/III trial for the treatment of non-union fractures

Bone Therapeutics’ pivotal phase III osteonecrosis trial with PREOB® hits a new milestone - 30 centres across Europe now active

  • Read more about Bone Therapeutics’ pivotal phase III osteonecrosis trial with PREOB® hits a new milestone - 30 centres across Europe now active

Pagination

  • Next page ››
Subscribe to 2013
Wallonie Eu Flag

BioSenic SA
Rue Granbonpré 11 – Bâtiment H (bte 24)
1435 Mont-St-Guibert – Belgium
T.: +32 493 09 73 66
info@biosenic.com
Contact

Sign upfor our press releases

Receive information about BioSenic

Sign Up

Footer menu

  • Privacy Policy
  • Trademarks Copyrights
  • Users conditions